2019 and Psychedelic therapy - Mental Health Clinicians

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2019

Psychedelic therapy

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Mad in America

AUGUST 14, 2024

By 2019, two Phase 3 trials of aducanumab were terminated early because the drug wasn’t improving outcomes and was clearly causing harm (a large percentage of the participants were experiencing brain bleeding known as ARIA). And the FDA is not required to follow the advice of its advisory committees.

Pharmaceuticals

Pharmaceuticals Nonprofits Psychedelic therapy

Set, Setting, Forgetting: Silence on Abuse in Psychedelic Therapy Histories

Mad in America

DECEMBER 18, 2024

Psychedelic therapy advocates consistently dismiss these concerns as exaggerated or isolated incidents that are inevitable in any therapy. Multiple former patients came forward with accounts of Ingrasci sexually abusing them during therapy sessions with MDMA and ketamine (see also: Psymposia reporting in 2019 ).

Psychedelic therapy

Psychedelic therapy Legal Aging and mental health Self-awareness

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Set, Setting, Forgetting: Silence on Abuse in Psychedelic Therapy Histories

Stay Connected